Source: International Business Times
The acquisition gives Lilly access to AtaiBeckley's most advanced experimental treatment, BPL-003, a nasal spray that is currently being evaluated in Phase 3 clinical trials for treatment-resistant depression. Scott Olson/Getty Images Eli Lilly is making its biggest move yet into the rapidly evolving field of psychedelic medicine, acquiring clinical-stage biotechnology company AtaiBeckley in a deal valued at up to $3. 8 billion.
Aller á la Source
Nouvelles connexes
